id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333234-yvixy77x	Triposkiadis, Filippos	Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications	2020-09-01		.txt	text/plain	3226	153	46	While the potential for benefit with the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and the risks from stopping them is more evident, potential harm by RAΑSi may also be caused by the increase in the activity of the ACE2 receptor, the inefficient counter regulatory axis in the lungs in which the proinflammatory prolyloligopeptidase (POP) is the main enzyme responsible for the conversion of deleterious angiotensin (ANG) II to protective ANG [1–7] and the proinflammatory properties of ACE2(+) cells infected with SARS-CoV-2. In a recent statement of the European Medicinal Agencies (EMA), it is emphasized (10 June 2020 EMA/284513/2020): "Recent observational studies of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, also called sartans) have not shown an effect of these medicines on the risk of becoming infected with severe acute respiratory syndrome coronavirus 2 (the virus causing COVID-19) and do not indicate a negative impact on the outcome for patients with COVID-19 disease.	./cache/cord-333234-yvixy77x.txt	./txt/cord-333234-yvixy77x.txt